🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT06681974
Recruiting Phase 3

OROPHARYNGEAL MYOFUNCTIONAL THERAPY IN OBSTRUCTIVE SLEEP APNEA

NCT06681974 · tracked via the Priya Life Science Spain tracker
Phase
Phase 3
Started
2023-05-01
Last updated
2024-11-14

Condition(s) studied

Obstructive Sleep Apnea

Investigational drug(s) / intervention(s)

CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.EXPERIMENTAL: program of exercises that will be composed of 4 blocks

CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.: * Establish a regular sleep schedule * Do not stay in bed longer than our regular sleep schedule. * Avoid naps during the day * Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed. * Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed. * Follow a healthy bedtime routine * Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances.

EXPERIMENTAL: program of exercises that will be composed of 4 blocks: the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).

Study summary

Obstructive Sleep Apnea (OSA) is a prevalent nocturnal breathing disorder among the general population. Oropharyngeal myofunctional therapy (OMT) is an alternative conservative treatment used to improve OSA, associated health problems, and to improve the efficacy and tolerability of CPAP.

The objective is to determine the effect of OMT in the general population with mild-moderate OSA.

The overall study design will be a randomized controlled clinical trial with parallel groups. Both the control group and the intervention group will receive the same indications on the hygienic-dietary measures to be followed. The intervention group will also follow an exercise program based on OMT for 20 weeks. The effect on the apnea-hypopnea index and other variables will be determined by means of respiratory polygraphy before and after the intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Acceptance and signature of the informed consent * Diagnosis of OSA with mild-moderate AHI without criteria for treatment with CPAP and/or other treatments (DAM). * Patients who refused CPAP, were not candidates and/or refused DAM. * Age \> 18 years and \< 70 years Exclusion Criteria: * Craniofacial malformations. Severe developmental delay. Intellectual disability. * Diagnosis of neurodegenerative disease. * Limited tongue mobility/presence of ankyloglossia as well as Temporo-Mandibular Joint pathology. * Regular use of hypnotic medications * Bulbar pathologies * AHI of central origin above 50% of the total sleep time. * Obesity grade II or more. * Severe cardiovascular, neuromuscular or pulmonary pathology or chronic domiciliary oxygen use. Hypoventilation-obesity syndrome. * Refuse to participate in the clinical trial despite fulfilling the inclusion criteria and not presenting any exclusion criteria.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital universitario Marques de Valdecilla Santander Spain Recruiting

More Instituto de Investigación Marqués de Valdecilla trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06681974 on ClinicalTrials.gov ↗ ← All trials in Spain